HANTASH BASIL M has a total of 17 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are MED COLLEGE GEORGIA RES INST, DAVID GLADSTONE INST and ANTICANCER INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | WIPO (World Intellectual Property Organization) | 2 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Agriculture | |
#6 | Medical technology | |
#7 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Specific use of cosmetics | |
#7 | Animal care | |
#8 | Object sterilising | |
#9 | Diagnosis and surgery | |
#10 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Hantash Basil M | 17 |
#2 | Debenedictis Leonard C | 3 |
#3 | Frangineas George | 3 |
#4 | Zhao Longmei | 2 |
#5 | Ubeid Anan Abu | 1 |
#6 | Wang Ying | 1 |
#7 | Chan Kin F | 1 |
Publication | Filing date | Title |
---|---|---|
US2015118286A1 | Peptide tyrosinase inhibitors and uses thereof | |
US2011081326A1 | Compositions comprising mesenchymal stem cell-derived fibroblasts | |
US2008254006A1 | Treatment of alopecia by micropore delivery of stem cells | |
US2010055785A1 | Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells | |
US2008261305A1 | TGF-beta-MEDIATED OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS | |
US2008262482A1 | Method and device for tightening tissue using electromagnetic radiation | |
US2008063732A1 | Method of increasing the efficacy of neurotoxin | |
US2007212335A1 | Treatment of alopecia by micropore delivery of stem cells |